Journal Article Review Epublish 10 citations
PubMed: 37822800 DOI: 10.2147/DMSO.S430740
The Impact of Intermittent Fasting on Non-Alcoholic Fatty Liver Disease in Older Adults: A Review of Clinicaltrials.gov Registry.
Diabetes Metab Syndr Obes 16:3115-3121
Authors: Nasser M Alorfi, Ahmed M Ashour
Affiliations
- Pharmacology and Toxicology Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Abstract
Background
Non-alcoholic fatty liver disease (NAFLD) is a predominant health condition across the world due to its rising prevalence and association with various metabolic disorders. Intermittent fasting (IF) has attracted increasing attention as a dietary approach to addressing weight management and enhancing metabolic well-being, and its potential effects on NAFLD have been a topic of growing research interest.
Aim
This review aims to critically evaluate the current evidence on IF's impact on NAFLD, including the mechanisms underlying the observed effects in older adults (65+).
Methods
A comprehensive search of Clinicaltrials.gov was conducted to identify relevant studies that investigated the effects of IF on NAFLD in older adults (65+). Data on study design, sample size, intervention details, and outcomes related to NAFLD were extracted and analyzed.
Results
As of April 12th, 2023, there were 1304 clinical trials on NAFLD. Most of these were interventional studies. The investigation focused on completed studies and found that limited clinical trials were identified with limited interventional measures. Only five out of the 1304 studies on NAFLD involved IF. Basic and advanced outcome measures were examined.
Conclusion
Although some studies suggest that IF may have potential benefits for NAFLD, the evidence is still limited and inconclusive.
MeSH
Liver Diseases, Registries, Fasting, Life Style, Metabolic Diseases, Non-Alcoholic Fatty Liver Disease, Liver, Alcoholics, Fatty Liver, Fatty Liver, Alcoholic, Intermittent Fasting
Cited by
- The effect of ertugliflozin in patients with nonalcoholic fatty liver disease associated with type 2 diabetes mellitus: A randomized controlled trial. Medicine (Baltimore), 2024
- Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov Analysis. Diabetes Metab Syndr Obes, 2024
- Intermittent fasting as a treatment for obesity in young people: a scoping review. NPJ Metab Health Dis, 2025
- Intermittent Fasting in Youth: A Scoping Review. Res Sq, 2024
- Reshaping lipid metabolism with long-term alternate day feeding in type 2 diabetes mice. NPJ Metab Health Dis, 2025
- Role of Fasting in the Management of Non-alcoholic Fatty Liver Disease (NAFLD): A Systematic Review of Clinical Trials. Cureus, 2025